Encysive TBC3711 On Clinical Hold
Encysive's next-generation selective endothelin receptor antagonist TBC3711 is subject to a clinical hold following an unexpected result in pre-clinical work
Encysive's next-generation selective endothelin receptor antagonist TBC3711 is subject to a clinical hold following an unexpected result in pre-clinical work